Literature DB >> 556842

Pulmonary hypertension in the perinatal aspiration syndromes.

W W Fox, M H Gewitz, R Dinwiddie, W H Drummond, G J Peckham.   

Abstract

Ten patients clinically diagnosed as having perinatal aspiration syndromes were found to have pulmonary hypertension. These infants were either term or postmature babies and had the following characteristics: (1) systemic or suprasystemic levels of pulmonary artery pressure (range, 50 to 117 mm Hg); (2) a degree of pulmonary hypertension not related to the degree of aspiration evident on chest roentgenograms; (3) evidence of right-to-left shunting at the ductal or foramen ovale level; and (4) sustained severe hypoxemia despite 100% inspired oxygen concentration. The overall mortality for the group was 50%. Since these patients had marked clinical and physiologic similarities to patients previously reported as having the persistent fetal circulation syndrome (PFC), they were classified as having "PFC with aspiration." The existence of pulmonary hypertension should be suspected despite roentgenographic evidence of aspiration in any patient who also manifests the clinical characteristics of PFC because its treatment may alter the prognosis of such patients.

Entities:  

Mesh:

Year:  1977        PMID: 556842

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  11 in total

1.  Persistent fetal circulation: an evolving clinical and radiographic concept of pulmonary hypertension of the newborn.

Authors:  D F Merten; B W Goetzman; R P Wennberg
Journal:  Pediatr Radiol       Date:  1977-09-01

2.  Decreased endothelial nitric oxide synthase expression and function contribute to impaired mitochondrial biogenesis and oxidative stress in fetal lambs with persistent pulmonary hypertension.

Authors:  Adeleye J Afolayan; Annie Eis; Maxwell Alexander; Teresa Michalkiewicz; Ru-Jeng Teng; Satyan Lakshminrusimha; Girija G Konduri
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2015-10-30       Impact factor: 5.464

3.  Left and right ventricular systolic time intervals in the newborn. Usefulness and limitation in distinguishing respiratory disease from transposition of the great arteries.

Authors:  H P Gutgesell; W W Pinsky; D F Duff; J Adams; D G McNamara
Journal:  Br Heart J       Date:  1979-07

4.  Oxygen modulates prostacyclin synthesis in ovine fetal pulmonary arteries by an effect on cyclooxygenase.

Authors:  P W Shaul; W B Campbell; M A Farrar; R R Magness
Journal:  J Clin Invest       Date:  1992-12       Impact factor: 14.808

5.  Persistent pulmonary arterial hypertension of the newborn.

Authors:  A Narang; O N Bhakoo; P M Nair; V Bhandari
Journal:  Indian J Pediatr       Date:  1992 Nov-Dec       Impact factor: 1.967

6.  Perinatal asphyxia II: Clinical management of multisystemic sequelae.

Authors:  A K Fomufod; P L White
Journal:  J Natl Med Assoc       Date:  1979-11       Impact factor: 1.798

7.  Effects of magnesium sulphate and nitric oxide in pulmonary hypertension induced by hypoxia in newborn piglets.

Authors:  C A Ryan; N N Finer; K J Barrington
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1994-11       Impact factor: 5.747

Review 8.  Advances in the diagnosis and management of persistent pulmonary hypertension of the newborn.

Authors:  G Ganesh Konduri; U Olivia Kim
Journal:  Pediatr Clin North Am       Date:  2009-06       Impact factor: 3.278

9.  Decreased Cyclic Guanosine Monophosphate-Protein Kinase G Signaling Impairs Angiogenesis in a Lamb Model of Persistent Pulmonary Hypertension of the Newborn.

Authors:  Megha Sharma; Ujala Rana; Chintamani Joshi; Teresa Michalkiewicz; Adeleye Afolayan; Abdul Parchur; Amit Joshi; Ru-Jeng Teng; Girija G Konduri
Journal:  Am J Respir Cell Mol Biol       Date:  2021-11       Impact factor: 6.914

10.  Antenatal betamethasone improves postnatal transition in late preterm lambs with persistent pulmonary hypertension of the newborn.

Authors:  Girija G Konduri; Ivane Bakhutashvili; Annie Eis; Adeleye Afolayan
Journal:  Pediatr Res       Date:  2013-01-31       Impact factor: 3.756

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.